Francesca Domenech Wuttke, new Chief Digital Officer and new member of the Management Board in Almirall
· Francesca Domenech Wuttke will be responsible for developing and executing the end-to-end digital strategy of the company and will report directly to Peter Guenter.
· She will lead the Digital Transformation, defining Almirall’s new digital governance model, developing and prioritizing the company Digital Project Portfolio and working closely with business stakeholders.
· The new Chief Digital Officer has extensive experience in major pharma companies and investment firms.
Almirall, S.A. has announced the appointment of Francesca Domenech Wuttke as the new Chief Digital Officer and member of the Management Board of the company.
In her new role, Francesca Domenech Wuttke will report directly to Peter Guenter, Chief Executive Officer, Almirall, and will be responsible for developing and executing the end-to-end digital strategy, a key pillar in the future success of Almirall.
She will lead the Digital Transformation for Almirall, defining the new digital governance model, developing and prioritizing the enterprise wide Digital Project Portfolio and working closely with all business stakeholders.
“Digital transformation in healthcare is a huge opportunity for any biopharmaceutical company. We are certain that Francesca is the best person to lead the transformation with Almirall”, explained Peter Guenter, Chief Executive Officer, Almirall. “She will join us after more than 25 years of international strategic, commercial and transactional experience. She has excellent firsthand knowledge of the potential that digital technology has in the healthcare industry, so we are fortunate to have her”.
During the last few years, Francesca has led European investments as Managing Director Europe for the Global Health Innovation Fund MSD’s venture capital arm. The fund is exclusively focused on investments in digital health solutions and services and there, she designed the investment thesis to accelerate the digital clinical trial ecosystem, with much success. For example, she invested in a digital clinical trial patient recruitment platform as well as a platform that interrogates electronic medical records for genomic phenotyping, clinical trial applications and Real World Evidence.
Previously, she also worked as Global Director, Commercial Strategy at Novartis and she was co-founder of Asten BioPharma Avisors, a healthcare consultancy that supports business development of biopharmaceutical companies interested in investments in biotechnology. During her experience in venture capital, private equity, start-ups, consulting and pharma companies, Francesca has shown a great ability to distill scientific and clinical data into investment opportunities, having prospected and evaluated hundreds of opportunities.
Francesca holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a B.A. in Biology and Society by the Cornell University College of Arts and Sciences. Francesca is an American citizen who lives with her family in Barcelona.
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed. The company, founded 75 years ago and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment to major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenues in 2017 were 755.8 million euros. More than 1,830 employees are devoted to Science.
For more information, please visit almirall.com linkedin.com/company/almirall
Media and Investors Relations Contact:
Media contact: Investors & Corporate Communications contact:
Marta Gállego Pablo Divasson del Fraile
Tel.: (+34) 915 31 42 67 Tel.: (+34) 93 291 30 87